Biological E. Ltd (BE) announced on Monday that the price of its Covid-19 vaccine Corbevax for private vaccination centres has been reduced to $250 from 840 per dose, inclusive of GST.
End users would pay $400 per dose, including taxes and administrative fees, according to the company in a statement.
Previously, the overall cost of the vaccine to end users in private vaccination centres was 990 per dose, including taxes and administration fees, it said.
When the country’s COVID-19 vaccination programme for children aged 12 to 14 years began in March, Corbevax vaccine was used, and its price was set at 145 for the government vaccination programme.
“BE has reduced the price of its vaccine in order to make it more affordable and to help expand its reach in order to protect the greatest number of children against the virus,” the company said.
The Emergency Use Authorization (EUA) for Biological E’s Corbevax for children aged 5 to 12 years and Bharat Biotech’s Covaxin for children aged 6 to 12 years was granted by India’s drug regulator in April this year.
Corbevax was developed in collaboration with Texas Children’s Hospital and Baylor College of Medicine. The company said it conducted Phase II and III multi-centre clinical trials in 624 children aged 5 to 12 and 12 to 18 years old before receiving EUA for vaccination.
